Sclerostin Antibodies

Santa Cruz Biotechnology features a diverse variety of Sclerostin Antibodies for investigating sclerostin's role in bone metabolism. Sclerostin Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Sclerostin is a glycoprotein produced by osteocytes that plays a critical role in bone homeostasis by inhibiting the Wnt signaling pathway, which is essential for bone formation. The regulation of sclerostin is vital for maintaining bone density and strength, making it a significant target for research in osteoporosis and other bone-related disorders. Understanding sclerostin function can provide insights into therapeutic strategies for enhancing bone health. Sclerostin research has revealed important mechanisms in bone development and remodeling. Ongoing studies continue to uncover new aspects of sclerostin's involvement in skeletal disorders and potential therapeutic applications. Current investigations focus on how sclerostin influences bone mass regulation and mineral homeostasis. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing bone biology knowledge and developing innovative treatments for bone-related conditions.